0.4061

13.37% 0.0479

Pre-market: .40 -0.0061 -1.50%

Heron Therapeutics Inc (HRTX)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Heron Therapeutics Inc stock is traded at $0.4061, with a volume of 3.50M. It is up +13.37% in the last 24 hours and up +28.72% over the past month. Heron Therapeutics Inc is a commercial-stage biotechnology company. The company is focused on improving the lives of patients by developing treatments and commercializing therapeutic solutions to address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.

Previous Close:

$0.3582

Open:

$0.3537

24h Volume:

3.50M

Relative Volume:

1.23

Market Cap:

$77.10M

Revenue:

$150.71M

Net Income/Loss:

$-30.94M

P/E Ratio:

-2.2982

EPS:

-0.1767

Net Cash Flow:

$-20.86M

1W Performance:

+9.76%

1M Performance:

+28.72%

6M Performance:

-52.39%

1Y Performance:

-68.27%

1-Day Range:

$0.00

1-Week Range:

$0.3207

$0.41

52-Week Range:

$0.261

$1.575

Heron Therapeutics Inc Stock (HRTX) Company Profile

Name

Heron Therapeutics Inc

Sector

Healthcare (1050)

Industry

Biotechnology (591)

Phone

(858) 251-4400

Address

4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO, CA

Employee

128

Twitter

Next Earnings Date

2026-11-03

Latest SEC Filings

HRTX's Discussions on Twitter

Compare HRTX vs VRTX, MRNA, REGN, ARGX, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
HRTX Heron Therapeutics Inc	0.4061	77.10M	150.71M	-30.94M	-20.86M	-0.1767
VRTX Vertex Pharmaceuticals Inc	510.08	129.29B	12.34B	4.34B	3.71B	16.87
MRNA Moderna Inc	225.00	89.83B	2.23B	-3.19B	-1.60B	-8.1462
REGN Regeneron Pharmaceuticals Inc	746.54	76.86B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	825.03	51.88B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	189.76	40.67B	742.00K	-1.37B	-1.07B	-7.0731

Heron Therapeutics Inc Stock (HRTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-11-26	Downgrade	H.C. Wainwright	Buy → Neutral
Jun-03-26	Downgrade	Needham	Buy → Hold
Jun-09-25	Initiated	H.C. Wainwright	Buy
Jun-13-24	Initiated	Rodman & Renshaw	Buy
Apr-23-24	Initiated	CapitalOne	Overweight
Mar-13-24	Reiterated	Needham	Buy
May-27-20	Initiated	Guggenheim	Buy
Feb-20-20	Reiterated	Needham	Buy
Jan-16-19	Reiterated	Needham	Buy
Apr-05-18	Initiated	Evercore ISI	Outperform
Mar-19-18	Reiterated	Mizuho	Buy
Mar-01-18	Reiterated	Needham	Buy
Jan-03-18	Initiated	Leerink Partners	Outperform
Sep-27-17	Initiated	Northland Capital	Outperform
Feb-27-17	Initiated	Needham	Buy
Oct-26-16	Initiated	Aegis Capital	Buy
Sep-06-16	Resumed	Lake Street	Buy
May-03-16	Initiated	Cantor Fitzgerald	Buy
Dec-10-15	Initiated	Lake Street	Buy
Sep-23-15	Reiterated	Leerink Partners	Outperform
Sep-02-15	Initiated	BofA/Merrill	Buy
Aug-03-15	Reiterated	Brean Capital	Buy
Jun-30-15	Reiterated	JMP Securities	Mkt Outperform
Jun-19-15	Reiterated	Leerink Partners	Outperform
Aug-07-14	Initiated	Noble Financial	Buy

View All

Heron Therapeutics Inc Stock (HRTX) Latest News

Oct 08, 2026

Heron Therapeutics stock gained 15.86 percent to USD 0.38 - AD HOC NEWS

Oct 08, 2026

Oct 07, 2026

Heron Therapeutics stock faces a guidance reset after Q2 loss - AD HOC NEWS

Oct 07, 2026

Oct 06, 2026

Heron Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2020 and Highlights Recent Corporate Updates - Lelezard

Oct 06, 2026

Oct 05, 2026

Heron Therapeutics stock fell 2.33 percent on October 2 - AD HOC NEWS

Oct 05, 2026

Sep 29, 2026

Form 8K Heron Therapeutics Inc For: 29 September By Investing.com - Investing.com Nigeria

Sep 29, 2026

Heron Therapeutics signs multi-product license agreement with Long Grove By Investing.com - Investing.com Nigeria

Sep 29, 2026

Heron Therapeutics signs multi-product license agreement with Long Grove - Investing.com

Sep 29, 2026

Sep 25, 2026

Heron Therapeutics, Inc. (NASDAQ:HRTX) Stock Has Consensus Target Price of $2.00 - MarketBeat

Sep 25, 2026

Sep 22, 2026